Shengnan Bao - Publications

Maintenance therapy in hormone receptor-positive and human epidermal growth factor receptor 2-positive metastatic breast cancer: a real-world multicenter retrospective study.

Journal: Frontiers in oncology

Published: September 11, 2025

Clinical, pathological and gene expression profiling of estrogen receptor discordance in breast cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 22, 2024

A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Journal: Cancers

Published: July 20, 2022

Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer.

Journal: Frontiers in immunology

Published: May 17, 2022

A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression.

Journal: Cell death discovery

Published: February 04, 2022

Which Has a Greater Impact on the Recurrence in Young Breast Cancer Patients: Recent Childbirth or Recent Breastfeeding?

Journal: The breast journal

Published: October 22, 2021

Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population-based study.

Journal: Cancer medicine

Published: July 09, 2021

Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials.

Journal: Annals of translational medicine

Published: April 15, 2021

Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer.

Journal: Frontiers in pharmacology

Published: June 28, 2020